Radicava Ors (Edaravone) Patent Expiration, LOE Window & CMS Spending

Radicava Ors (Edaravone) by Shionogi: FDA Orange Book LOE 2041-11-12, 0 AB generics, $394.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorShionogi
FDA Application & PathwayN215446 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-11-12
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$394.1M
2024 Medicare Part D Spend$375.7M
2024 Medicaid Spend$18.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel